Health-related quality of life among patients with postmenopausal osteoporosis treated with weekly and monthly bisphosphonates.

The present study was designed to assess the effect of monthly ibandronate on health-related quality of life (HR-QoL) in patients with postmenopausal osteoporosis previously treated with weekly bisphosphonates.
HR-QoL was assessed by Euroqol (EQ-5D) and Osteoporosis Targeted Quality of Life (OPTQoL) questionnaires.
The EQ-5D questionnaire showed significant improvement associated with ibandronate treatment, occurring in mobility (p < 0.01), usual activity (p < 0.01), pain/discomfort (p < 0.05), and anxiety/depression (p < 0.05). In addition, ibandronate treatment considerably improved patients' perceived health on a visual analog scale (p < 0.001). For the OPTQoL questionnaire, patients reported less physical difficulty (p < 0.001), fewer adaptations in their lives (p < 0.001), and less fear (p < 0.001) with ibandronate than with weekly bisphosphonates.
The study demonstrated that patients who were transferred from weekly bisphosphonates to a monthly ibandronate experienced improved HR-QoL.
AuthorsDarko Kastelan, Tonko Vlak, Petar Lozo, Marina Gradiser, Sime Mijic, Tatjana Nikolic, Blazenka Miskic, Dolores Car, Gordana Tajsic, Tina Dusek, Zrinka Jajic, Frane Grubisic, Tamara Poljicanin, Miro Bakula, Fedja Dzubur, Matilda Strizak-Ujevic, Mira Kadojic, Maja Radman, Maja Vugrinec, Zeljka Kuster, Marijeta Pekez, Endi Radovic, Ljubica Labar, Zeljka Crncevic-Orlic, Mirko Korsic
JournalEndocrine research (Endocr Res) Vol. 35 Issue 4 Pg. 165-73 ( 2010) ISSN: 1532-4206 [Electronic] England
PMID20868288 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Multicenter Study)
Chemical References
  • Bone Density Conservation Agents
  • Diphosphonates
  • ibandronic acid
  • Aged
  • Bone Density Conservation Agents (administration & dosage)
  • Chi-Square Distribution
  • Diphosphonates (administration & dosage)
  • Drug Administration Schedule
  • Female
  • Humans
  • Middle Aged
  • Osteoporosis, Postmenopausal (drug therapy, psychology)
  • Prospective Studies
  • Quality of Life
  • Surveys and Questionnaires

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: